Immunome, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.37 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.09, a 64.60% increase year-over-year.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.13, a 25.79% decline year-over-year.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.26, a 31.34% decline year-over-year.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.03.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $9.42, a 11.72% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $10.67, a 59.97% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $6.67, a 44.28% decline from fiscal 2022.
- Immunome, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $11.97.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.37 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $10.09 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $9.42 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $9.42 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $8.71 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $6.13 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $10.67 10-K · filed 2025-03-19 | |||
| 2024-09-30 | $8.18 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $8.43 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $8.26 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $6.67 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $11.56 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $11.56 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $12.03 10-Q · filed 2023-05-05 | |||
| 2022-12-31 | $11.97 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $12.20 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |